Toleris Biotherapeutics

Executive Summary

Toleris Biotherapeutics, founded in January 2024 and based in Würzburg, Germany, is a pioneering biotech company developing first-in-class AutoImmunity Modifying Biologics (AIM Bios). The company leverages a novel therapeutic approach inspired by the body's natural immune tolerance during pregnancy to treat autoimmune diseases. Led by an experienced team of scientists and entrepreneurs, Toleris aims to address significant unmet needs in autoimmune conditions through its proprietary platform. As a very early-stage private company with no disclosed pipeline or funding, the key risk and opportunity hinge on proof-of-concept data and capital raises. The approach is scientifically innovative but carries high preclinical risk.

Upcoming Catalysts (preview)

• Q4 2026Seed/Series A Funding Announcement60% success
• Q1 2027Publication of Preclinical Proof-of-Concept Data50% success
• Q3 2027IND-Enabling Study Initiation30% success